About Metagenomi
Metagenomi is a publicly listed company based in Berkeley (United States) founded in 2016 by Brian Thomas. Next-generation gene editing tools are developed for drug enhancement. Metagenomi has raised $376.37 million across 6 funding rounds from investors including Moderna, Bayer and Marshall Wace. The company has 202 employees. Its chief executive, as recorded, is Brian Thomas. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include Beam Therapeutics, DNAnexus and eGenesis; 3 of its 3 listed competitors have raised funding.
Company details
Metagenomi was founded in 2016 and is based in Berkeley, United States. Digital gene editing technologies are advanced by the company within the biotechnology sector for drug development purposes. A next-generation tool has been engineered to support drug enhancement and design. Operations center on creating editing solutions for therapeutic applications, with a focus on precision in genetic modifications.
- Headquarters Berkeley, United States
- Employees 202
- Founders Brian Thomas
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website metagenomi.co
- Social LinkedIn X
- Legal Name Metagenomi, Inc.
- Annual Revenue$25.21 M (USD)-51.79as on Dec 31, 2025
- Net Profit-$87.87 M (USD)-12.57as on Dec 31, 2025
- EBITDA-$90.7 M (USD)-8.63as on Dec 31, 2025
- Total Equity Funding$376.37M (USD)
in 6 rounds
- Latest Funding Round$100M (USD), Series B
Dec 2022
- InvestorsModerna
& 21 more
- Employee Count202
Funding Insights of Metagenomi
Metagenomi has successfully raised a total of $376.37M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $376.37M
- Total Rounds 6
- Last Round Series B — $100M
- First Round $26.37M
(Aug 2019)
- Investors Count 22
All 6 funding rounds of Metagenomi with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $100M | Series B | – | Novo Holdings, Catalio Capital Management | |
| Jan 2022 | $175M | Series B | – | PFM Health Sciences, Farallon Capital Management | |
| Mar 2021 | $10M | Series A | – | RA Capital Management, Bayer | |
| Nov 2020 | $65M | Series A | – | Humboldt Fund, Leaps by Bayer | |
| Aug 2019 | Debt – Conventional | – | – | – | |
| Aug 2019 | $26.37M | Series A | – | – | – |
22 investors in total: 22 institutional.
Investors in Metagenomi
Metagenomi has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include Moderna, Bayer and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Investments in healthcare companies are made by SymBiosis. | symbiosis.vc | Bentonville, United States | ||
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Deep Track Capital is engaged in biotechnology investment activities. | deeptrackcapital.com | Greenwich, United States | ||
Investment management services are provided focusing on healthcare innovation. | puravidainvestments.com | New York, United States | ||
Early-stage startups are invested in by sector-agnostic VC fund. | irvinginvestors.com | New York, United States | ||
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom |
Investor details for Metagenomi
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Metagenomi
23 people are tracked at Metagenomi (13 in leadership, 4 in board & advisors, 6 in team); the tracked headcount is 202.
| Name | Role | Group |
|---|---|---|
Brian Thomas | Founder & CEO | Leadership |
Jian Irish | President & COO | Leadership |
Elina Khurgin | Head Of Information Technology | Leadership |
Chris Brown | Head, Discovery | Leadership |
Maravilla Rasalan | CMC And CMO Management | Leadership |
Jeff Williamowsky | Associate Director, Business Operations | Leadership |
Pamela Wapnick | Chief Financial Officer | Leadership |
Matthew Wein | Vice President, Corporate Legal And Compliance | Leadership |
Sonya Cruz | Director Program Management And Business Operations | Leadership |
Marco Rosas | Director Of Finance | Leadership |
Nikki Griego Webber | Head Of Human Resources | Leadership |
Daniela S. A. Goltsman | Associate Director | Leadership |
Cory Sturtevant | Associate Director, IT Operations | Leadership |
Santhosh Palani | Director | Board & advisors |
Jürg Eckhardt | Director | Board & advisors |
Willard H. Dere | Director | Board & advisors |
Tom Schmitt | Scientific Advisor | Board & advisors |
Shailaja Chadha | Senior Program Management Specialist | Team |
Gloria Nam | Corporate Controller | Team |
Khak Khak Khayi | Research Associate | Team |
3 more people are available in the full profile.
Complete people profiles for Metagenomi
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Metagenomi
Metagenomi is a publicly listed company on the NASDAQ with ticker symbol MGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Feb 2024
- Listed onNASDAQ: MGX
- Listed entityMetagenomi, Inc.
- Exchange sectorHealth technology
- ISINUS59102M1045
- Share price$0.92 (-10.07% on the day) · 2026-10-13
- Market capitalisation$34.7M
- EPS (diluted, trailing year)$-2.49
- Volume (last session)265,784
Financials of Metagenomi
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $25.2M | -$87.9M | -$90.7M |
| 2024 | $52.3M | -$78.1M | -$83.5M |
| 2023 | $44.8M | -$68.2M | -$74.3M |
| 2022 | $17.2M | -$43.6M | -$42.9M |
| 2021 | $243,000 | -$21.4M | -$23.6M |
Detailed financial statements for Metagenomi
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Metagenomi
4 dated milestones of Metagenomi across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Metagenomi is founded.
- Funding First funding round of $26.4M.
- Funding Latest funding round, Series B, of $100.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Metagenomi
Metagenomi has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, DNAnexus and eGenesis.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. |
Detailed competitors of Metagenomi
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Metagenomi
The website of Metagenomi (metagenomi.co) receives about 4.7K visits a month and ranks #3,449,082 among all websites worldwide, #4,493 in Biotechnology and Pharmaceuticals.
- Monthly visits4.7K
▼ 8.2% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,449,082
among all websites
- Category rank#4,493
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.0
- Average visit38 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Metagenomi. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
rxwellness.net | rxwellness.net | 100% | #1,615,114 | – | |
entnova.com | entnova.com | 99% | #1,193,599 | – | |
hemophilianewstoday.com | hemophilianewstoday.com | 42% | #1,655,713 | – | |
arlingtonvaderm.com | arlingtonvaderm.com | 36% | #1,980,379 | – | |
tilicaremobiledetailing.com | tilicaremobiledetailing.com | 36% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Metagenomi
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Metagenomi (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Metagenomi
Complete news archive for Metagenomi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metagenomi
Metagenomi was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Metagenomi is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Brian Thomas is the CEO of Metagenomi, as recorded in our data. They have also founded this company.
Metagenomi is a funded company, having raised a total of $376.37M across 6 funding rounds to date. The company's 1st funding round was a Series A of $26.37M, raised on Aug 2019.
Metagenomi has 202 employees.
Annual revenue of Metagenomi is $25.21M as on Dec 31, 2025.
Metagenomi was founded in 2016 and is based in Berkeley, United States. Digital gene editing technologies are advanced by the company within the biotechnology sector for drug development purposes. A next-generation tool has been engineered to support drug enhancement and design. Operations center on creating editing solutions for therapeutic applications, with a focus on precision in genetic modifications.
Metagenomi's top competitors include DNAnexus, eGenesis and Beam Therapeutics.
Yes, Metagenomi is publicly traded on NASDAQ under the ticker symbol MGX.
Metagenomi has 22 investors. Key investors include Moderna, Bayer, Marshall Wace, Citadel, and RA Capital.